Süleyman Can

Dr. Süleyman Can

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2026 in Medicina
Verified
Journal Article
Open access
PDF file
VÇVeli Çakıcı
Veli Çakıcı
AOAYSEL OĞUZ
AYSEL OĞUZ
SCSüleyman Can
Süleyman Can
GKGizem bakır kahveci
Gizem bakır kahveci
HGHasibe Sintine Gür
Hasibe Sintine Gür
YÇYalçın Çırak
Yalçın Çırak
Background and Objectives: Medication adherence is a key determinant of treatment effectiveness in early-stage breast cancer, particularly during long-term systemic therapies. As breast cancer is increasingly diagnosed at younger ages, a growing number of women continue to carry active parenting responsibilities during treatment. However, the associations between parenting-related psychosocial factors and medication adherence remain insufficiently explored. This study aimed to examine the associations between parenting stress, spiritual well-being, and medication adherence in women with early-stage breast cancer who maintain active parenting roles. Materials and Methods: This multicenter, cross-sectional study included 432 women with early-stage (I–III) breast cancer receiving active systemic therapy across nine oncology centers. Parenting stress was assessed using the Parenting Stress Scale (PSS), spiritual well-being using the Functional Assessment of Chronic Illness Therapy–Spiritual Well-Being Scale (FACIT-Sp-12), and medication adherence using the 6-item Modified Morisky Adherence Scale (MMAS-6). Spearman correlation analyses and multivariable linear regression models were used to evaluate associations between variables. Mediation analysis was performed using Hayes’ PROCESS macro (Model 4) with 5000 bootstrap samples to assess statistical mediation. Results: Parenting stress was positively associated with poorer medication adherence (ρ = 0.248, p < 0.01), whereas spiritual well-being was negatively associated with non-adherence (ρ = −0.225, p < 0.01). Parenting stress showed a strong inverse association with spiritual well-being (ρ = −0.597, p < 0.01). In multivariable regression analyses, both parenting stress and spiritual well-being were independently associated with medication adherence (β = 0.180, p = 0.002 and β = −0.199, p = 0.001, respectively). Mediation analysis demonstrated a significant indirect statistical association between parenting stress and medication adherence through spiritual well-being (indirect effect = 0.0155), consistent with partial statistical mediation. Conclusions: Medication adherence among women with early-stage breast cancer and active parenting responsibilities is associated with psychosocial context in addition to clinical factors. Parenting stress is associated with poorer adherence, whereas greater spiritual well-being is associated with better adherence within a statistical mediation framework. These findings generate hypotheses for future longitudinal and interventional studies.

27 January 2026 in TURKISH JOURNAL of CLINICS and LABORATORY
Verified
Journal Article
Closed access
SCSüleyman Can
Süleyman Can
Aim: The aim of this study was to evaluate the relationship between glycemic control (HbA₁c), duration of diabetes, and body mass index (BMI) and macrovascular and microvascular complications (MACV and MICV) in patients with type 2 diabetes mellitus (T2DM).Material and Methods: In this retrospective cross-sectional study, baseline data from 902 individuals diagnosed with type 2 diabetes mellitus (T2DM) at the Diabetes Outpatient Clinic of Istanbul Training and Research Hospital were evaluated. Participants were classified based on HbA₁c level (5 years), and BMI (

Verified
Journal Article
Open access
PDF file
SCSüleyman Can
Süleyman Can
VÇVeli Çakıcı
Veli Çakıcı
GKGizem bakır kahveci
Gizem bakır kahveci
ŞEŞeyma Eroğlu
Şeyma Eroğlu
BTBurak Tok
Burak Tok
IGivo gokmen
ivo gokmen
Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti-vascular endothelial growth factor (VEGF)-based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusions: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF-based strategies, warranting prospective validation.

31 December 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
SCSüleyman Can
Süleyman Can
VÇVeli Çakıcı
Veli Çakıcı
GKGizem bakır kahveci
Gizem bakır kahveci
ŞEŞeyma Eroğlu
Şeyma Eroğlu
BTBurak Tok
Burak Tok
IGivo gokmen
ivo gokmen
Objective: In metastatic colorectal cancer (mCRC), mucinous histology has been associated with poor clinical outcomes, particularly in the presence of peritoneal metastasis. However, it remains unclear whether mucinous histology exerts a context-dependent effect on treatment outcomes by modifying the efficacy of anti–vascular endothelial growth factor (VEGF)–based therapies independently of metastatic dissemination patterns and chemotherapy backbone. Methods: We retrospectively analyzed 250 patients with mCRC treated with bevacizumab-containing systemic therapy. Tumors were classified as mucinous (n = 52) or non-mucinous (n = 198). Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Cox proportional hazards regression models were applied for univariate and multivariate analyses. Predefined subgroup analyses were conducted according to peritoneal metastasis status and chemotherapy backbone (oxaliplatin- or irinotecan-based). A 6-month landmark analysis was performed to reduce early progression bias. Interaction analyses evaluated potential effect modification between histology, peritoneal metastasis, and chemotherapy backbone. Results: Mucinous tumors were more frequently right-sided and strongly associated with peritoneal metastasis. In the overall cohort, mucinous histology was associated with significantly longer median PFS compared with non-mucinous histology (22.9 vs. 11.9 months; p < 0.001). This benefit was driven by patients with peritoneal metastasis, in whom mucinous histology was associated with markedly prolonged PFS (23.9 vs. 8.7 months; p < 0.001). No significant PFS difference according to histology was observed in patients without peritoneal metastasis. On multivariate analysis, mucinous histology remained independently associated with improved PFS (HR 0.44; 95% CI 0.25–0.78; p = 0.005), an effect preserved in the landmark cohort (HR 0.39; 95% CI 0.26–0.59; p < 0.001). A significant interaction between mucinous histology and peritoneal metastasis was observed (p for interaction = 0.040), indicating that the prognostic impact of histology differed according to metastatic pattern. No significant PFS difference or interaction was detected according to chemotherapy backbone within the mucinous subgroup. Conclusion: Among bevacizumab-treated patients with mCRC, mucinous histology—particularly in the presence of peritoneal metastasis—is associated with a pronounced PFS advantage independent of chemotherapy backbone. These findings suggest that mucinous peritoneal mCRC represents a biologically and clinically distinct subgroup that may derive context-specific and disproportionate benefit from anti-VEGF–based strategies, warranting prospective validation.

30 December 2025 in Medical Science and Discovery
Verified
Journal Article
Open access
SCSüleyman Can
Süleyman Can
Dear Editor, We read with great interest the pivotal report on dual immune checkpoint blockade (anti–PD-1/PD-L1 plus anti–CTLA-4) in advanced malignancies, which highlighted the clinical activity of combination immunotherapy in a large cohort (1). While combination regimens can provide meaningful efficacy outcomes, the toxicity burden remains a defining limitation. In the referenced trial, high-grade immune-related adverse events (irAEs), frequent treatment interruptions, and a non-negligible risk of fatal toxicity were notable alongside the efficacy signals (2). Current toxicity management frameworks in major guidelines (including NCCN and ESMO) provide comprehensive algorithms for irAE recognition and treatment; however, these recommendations have largely been shaped by monotherapy experience and selected trial populations (3). In routine practice, clinicians increasingly observe that combination regimens may generate earlier onset, higher severity, and more complex multisystem irAEs than those anticipated from guideline-based expectations derived predominantly from single-agent paradigms (4). Importantly, pharmacovigilance data reinforce this concern. Analyses of spontaneous reporting systems (e.g., FAERS, VigiBase, and JADER/PMDA) consistently demonstrate disproportionately higher reporting of severe irAEs with combination ICI regimens compared with monotherapy, supporting a signal of increased real-world toxicity burden (5-7). These findings should be interpreted as reporting/association signals (disproportionality) rather than incidence estimates; nevertheless, their concordance across databases suggests that the real-world safety profile of combination ICIs warrants heightened attention. Clinical Significance and Current Evidence Recent real-world and pharmacovigilance analyses have reported an increased likelihood of severe irAE reporting with combination regimens relative to single-agent therapy, including signals for organ-specific toxicities such as hepatitis, colitis, pneumonitis, and myocarditis (8-11). Likewise, meta-analytic evidence indicates that combination immunotherapy yields higher overall irAE rates than monotherapy across multiple settings; for example, in metastatic melanoma, overall irAE frequency has been reported as higher with combination therapy compared with single-agent ICI (12). Collectively, these data suggest that rare but potentially fatal toxicities—particularly myocarditis and severe neurologic syndromes—may occur at clinically meaningful rates and require proactive mitigation strategies (13). From a practical standpoint, irAEs under combination regimens often show earlier presentation, higher-grade severity, and greater need for immunosuppressive escalation, including steroid-refractory cases requiring second-line agents (e.g., infliximab, mycophenolate mofetil, vedolizumab, or other targeted immunosuppression) (14). Recent real-world cohort reports further indicate that hepatotoxicity, colitis, endocrine toxicities, pulmonary toxicity, and cardiotoxicity remain among the most clinically consequential events, frequently driving dose delays, prolonged immunosuppression, and permanent discontinuation (15). The burden is particularly pronounced in older patients and those with poorer performance status or significant comorbidities, where severe toxicity risk appears elevated and outcomes can be compromised by treatment discontinuation and prolonged recovery (16). Conclusions and Recommendations Taken together, contemporary evidence suggests that the toxicity profile of combination ICI regimens may exceed what clinicians expect when extrapolating from monotherapy-based guideline paradigms. We believe several practical steps could improve safety: Early recognition and intensified monitoring during the initial treatment period (when severe irAEs often emerge) (13). Structured, multidisciplinary toxicity pathways (oncology, gastroenterology, pulmonology, cardiology, endocrinology, rheumatology) to shorten time-to-treatment for severe irAEs (3). Risk-adapted patient selection incorporating age, performance status, comorbidity burden, prior autoimmunity, and organ reserve, with explicit counseling on discontinuation risk (17). Guideline refinements that clearly distinguish combination-regimen toxicity phenotypes from monotherapy and integrate high-quality real-world safety signals (pharmacovigilance + prospective observational cohorts). We respectfully suggest that future guideline updates include a dedicated section on combination ICI-specific toxicity patterns, emphasizing early severe irAE recognition, escalation strategies for steroid-refractory events, and risk stratification in vulnerable subgroups. Sincerely

22 October 2026 in Journal of Cancer Immunology
Verified
Journal Article
Open access
PDF file
SCSüleyman Can
Süleyman Can
Immune checkpoint inhibitors (ICIs) have transformed the natural history of several advanced/metastatic malignancies, producing durable responses that may persist after therapy is stopped. Yet the optimal treatment duration remains uncertain.